Children With Idiopathic Short Stature: An Expanding Role for Genetic Investigation in Their Medical Evaluation
- PMID: 38679385
- DOI: 10.1016/j.eprac.2024.04.009
Children With Idiopathic Short Stature: An Expanding Role for Genetic Investigation in Their Medical Evaluation
Abstract
Short stature in children is a common reason for referral to a pediatric endocrinologist. Many genetic, nutritional, psychological, illness-related, and hormonal causes must be excluded before labeling as idiopathic. Idiopathic short stature is not a diagnosis, but rather describes a large, heterogeneous group of children, who are short and often slowly growing. As new testing paradigms become available, the pool of patients labeled as idiopathic will shrink, although most will have a polygenic cause. Given that many of the new diagnoses are involved in growth plate biology, physical examination should assess for subtle dysmorphology or disproportion of the skeleton that may indicate a heterozygous mutation that in its homozygous state would be apparent. When laboratory evaluations are negative, one may consider genetic testing, such as targeted gene or gene panel, comparative genomic hybridization, or whole exome or whole genome sequencing (respectively). With a known genetic diagnosis, targeted therapy may be possible rather than recombinant human growth hormone, where response is generally poorer than that for children with growth hormone deficiency, because the variety of diagnoses may have varying growth hormone sensitivity. A firm diagnosis has heuristic value: to truncate further diagnostic evaluation, alert the clinician to other possible comorbidities, inform the family for genetic counseling, and direct appropriate targeted therapy, if available.
Keywords: aromatase inhibitors; genetic testing; growth; growth hormone; idiopathic short stature; sex steroids.
Copyright © 2024 AACE. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Disclosure A.D.R. consults for Ascendis Pharma, Antares Pharma, BioMarin Pharmaceuticals, Pfizer Pharma, Tolmar Pharma, the United States Anti-Doping Agency (USADA), and the World Anti-Doping Agency (WADA). L.E.C. serves as a sub-PI (not receiving salary support) on investigator-initiated grant from Pfizer Global Medical Grant Growth Hormone Research to Boston Children’s Hospital. Site PI for Aeterna Zentaris.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
